NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

NEMAURA MEDICAL, INC. (OTCMKTS:NMRD) Files An 8-K Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 9.01. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

Story continues below

On July 10, 2017 the Registrant’s Board of Directors acting by unanimous written consent, amended “Article II – Stockholders” of the Company’s Bylaws to include Section 10 as follows,

Prior to the amendment, the Company’s Bylaws did not have any provision allowing for action by consent of the stockholders. The Bylaws expressly provide that the Bylaws may amended or repealed by the affirmative vote of a majority of the Board, except the Board may not amend or repeal any Bylaw which expressly provides that the Board may not amend or repeal that Bylaw provision.

Item 9.01. Financial Statement and Exhibits.

(d) Exhibits.

Exhibit No.

Description

3(ii)

Text of the Amendment to Registrant’s Bylaws


Nemaura Medical Inc. Exhibit
EX-3.II 2 ex3xii.htm EXHIBIT 3(II0 Exhibit 3(ii) “Article II – Stockholders” of the Company’s Bylaws has been amended to include Section 10 as follows: “10.  ACTION BY CONSENT. Any action required or permitted by law or by the Articles of Incorporation to be taken at any meeting of the stockholders may be taken without a meeting,…
To view the full exhibit click here

About NEMAURA MEDICAL, INC. (OTCMKTS:NMRD)

Nemaura Medical, Inc. is a holding company. The Company owns a diagnostic medical device company specializing in discovering, developing and commercializing specialty medical devices. The Company’s focus is on the development of a continuous glucose monitoring (CGM) device, which consists of a disposable patch containing a sensor, and a non-disposable miniature electronic watch with a re-chargeable power source. CGM through a non-invasive patch can enable early detection of subtle changes in blood glucose levels. The Company, through its operating subsidiaries, performs medical device research and manufacturing of a CGM, named sugarBEAT. The sugarBEAT device is a non-invasive, wireless device for use by persons with Type I and Type II diabetes, and may also be used to screen pre-diabetic patients. The sugarBEAT device extracts analytes, such as glucose, to the surface of the skin in a non-invasive manner where it is measured using sensors and interpreted using an algorithm.

An ad to help with our costs